Available to sourceHuman Prescription DrugOphthalmic & Otic

RETEVMO (selpercatinib)

120 mg/1 · Coated Tablet

By Eli Lilly and Company

NDC: 0002-6120
Route: Oral
Therapeutic class: Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor , Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]
Marketing category: NDA

Package sizes

60 TABLET, COATED in 1 BOTTLE (0002-6120-60)NDC 0002-6120-60Available to order

Additional information

Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.

Request this medication

Send a request and we'll respond with availability, lot details, and pricing within 2 business hours.

Related in Ophthalmic & Otic

See all →